Drug intelligence / Profile preview

H02 + CHOP

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous, Oral

Overview

H02 + CHOP is not a standard or widely recognized drug regimen name in oncology. "CHOP" is a well-established combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin (also known as hydroxydaunorubicin or Adriamycin), vincristine (Oncovin), and prednisone or prednisolone. It is primarily used to treat non-Hodgkin lymphoma and other lymphoid malignancies[1][2][4][5]. The mechanism of action for the CHOP regimen involves multiple cytotoxic effects on rapidly dividing cancer cells through DNA alkylation, inhibition of topoisomerase II, microtubule disruption, and immunosuppression. The prefix "H02" does not correspond to any known pharmaceutical agent, code name, or established modification of the CHOP protocol in current clinical practice or literature. It may be an internal code for a clinical trial arm, investigational agent added to CHOP (such as an experimental monoclonal antibody), or could represent a typographical error.

Other names: H02 plus CHOPH-02 plus CHOPH 02 plus CHOPH02-CHOPH-02-CHOPH 02-CHOPrituximab biosimilar H02 + CHOP

Targets

CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on H02 + CHOP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H02 + CHOP.

Explore the full profile